Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AbbVieXSWX:ABBV +2.89%67 EV-to-EBITDA is 30.72 as of Jul. 19, 2026, which is 83% above its 10-year median of 16.79. GuruFocus rates XSWX:ABBV with a GF Score™ of 67/100 and a GF Value™ of CHF168.24 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 741 Drug Manufacturers companies, AbbVie ranks worse than 80.43% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AbbVie's enterprise value is CHF415,260 Mil.
AbbVie's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was CHF13,517 Mil. Therefore, AbbVie's EV-to-EBITDA for today is 30.72.
The historical rank and industry rank for AbbVie's EV-to-EBITDA or its related term are showing as below:
XSWX:ABBV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.36 Med: 16.79 Max: 37.66
Current: 30.33
During the past 13 years, the highest EV-to-EBITDA of AbbVie was 37.66. The lowest was 10.36. And the median was 16.79.
XSWX:ABBV's EV-to-EBITDA is ranked worse than 80.43% of 741
companies
in the Drug Manufacturers industry
Industry Median: 13.01
vs XSWX:ABBV: 30.33
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-19), AbbVie's stock price is CHF208.35.
AbbVie's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF1.623. Therefore, AbbVie's PE Ratio (TTM) for today is 128.37.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
AbbVie (XSWX:ABBV) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AbbVie's share price for today is CHF208.35.
AbbVie's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1.623.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for AbbVie's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ABBV vs MRK, JNJ, AMGN: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, AbbVie's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbbVie EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AbbVie's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AbbVie's EV-to-EBITDA falls into.
AbbVie's current Enterprise Value is CHF415,260 Mil.
AbbVie's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF13,517 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbbVie (XSWX:ABBV) has a EV-to-EBITDA of 30.72 as of Jul. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AbbVie. This is 83% above median its historical median of 16.79. Over the past decade, AbbVie's EV-to-EBITDA has ranged from 10.36 to 37.66. According to the industry distribution chart, AbbVie ranks #596 out of 741 companies in the Drug Manufacturers industry, placing it in the top 80.4%.
Is AbbVie's EV-to-EBITDA too high?
AbbVie's current EV-to-EBITDA of 30.72 is 83% above median its 10-year median of 16.79. Over the past 10 years, this metric has ranged from a low of 10.36 to a high of 37.66. The Drug Manufacturers industry median EV-to-EBITDA is 13.01. AbbVie's value of 30.72 is 136.1% above this industry median. Based on the distribution chart, AbbVie ranks #596 out of 741 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AbbVie has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's EV-to-EBITDA compare to MRK and JNJ?
According to the Drug Manufacturers industry distribution chart, AbbVie ranks #596 out of 741 companies for EV-to-EBITDA. This places AbbVie in the lower half of its industry. The industry median EV-to-EBITDA is 13.01. AbbVie's value of 30.72 is 136.1% above this benchmark. Historically, AbbVie's own EV-to-EBITDA has ranged from 10.36 to 37.66 over the past decade. While the company's 10-year median is 16.79 vs. the industry median of 13.01, AbbVie has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.01, based on 741 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbbVie's current EV-to-EBITDA of 30.72 is 136.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AbbVie. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbbVie's current EV-to-EBITDA is 30.72, which is 83% above median its own 10-year median of 16.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (XSWX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF168.24, compared to a current price of CHF208.35 — trading 23.8% above its estimated fair value. The current EV-to-EBITDA is 30.72, which is 83% above median its 10-year median of 16.79 and 136.1% above the Drug Manufacturers industry median of 13.01. AbbVie's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For AbbVie (XSWX:ABBV), the current EV-to-EBITDA is 30.72 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbbVie (XSWX:ABBV) Overvalued in 2026?
Based on GuruFocus' analysis, AbbVie stock appears to be overvalued.
The current stock price of CHF208.35 is trading 23.8% above its estimated GF Value™ of CHF168.24.
GuruFocus considers AbbVie to be Modestly Overvalued.
Key valuation signals for XSWX:ABBV:
EV-to-EBITDA: 30.72 (83% above median its 10-year median of 16.79)
GF Value™: CHF168.24 vs. price of CHF208.35 (23.8% above fair value)
Industry Position: 136.1% above the Drug Manufacturers median (#596 of 741)
No single metric tells the full story. See the XSWX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
67GF Score
Get the complete analysis for XSWX:ABBV
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ABBV has been successfully added to your 
